Abstract
Identifying the factors responsible for variability of treatment response is a central objective of clinical research. Specially designed pharmacogenomic studies have identified a handful of individual mutations modulating the effect of specific drugs. However, the extent to which drug response variability is driven by genetics is largely unknown, partly due to the small sample sizes of prospective pharmacogenomic trials. In this work, we develop a framework to study the genetic architecture of response to commonly prescribed drugs in large biobanks coupled with electronic health records. Our framework leverages concepts from gene-environment interaction testing, including novel interaction models at the level of genes, polygenic scores (PGS), and genome-wide heritability. We quantified the heritability of response to statins, metformin, warfarin, and methotrexate in 342,257 UK Biobank participants. Our results show that genetic variation modifies the primary effect of statins on LDL cholesterol (9% heritable) as well as its side effects on hemoglobin A1c and blood glucose (10% and 11% heritable, respectively). Next, we identified dozens of specific genes that modify drug response, which we then replicated in a retrospective pharmacogenomic study. Finally, we found that PGS accuracy varies up to 2-fold depending on treatment status, showing that the current approach of building PGS using mostly healthy individuals is likely to underperform in clinical contexts. Together, our results provide a framework for characterizing the genetic architecture of drug response using cross-sectional data.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by National Institutes of Health, grants 1R01ES029929-01 to J.F.A. and N.Z., and R35GM150822 and K25HL157603 to A.W.D.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted using the UK Biobank Resource under application 33127 and all data collection was done by the UK Biobank prior to this project.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
No data was produced in the present work. This research was conducted using the UK Biobank Resource under application 33127. We thank the participants of the UK Biobank for making this work possible.
